Shares of Repro-Med Systems KRMD decreased 2.2% in after-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share decreased 200.00% year over year to ($0.02), which were in line with the estimate of ($0.02).
Revenue of $5,528,000 declined by 28.29% from the same period last year, which beat the estimate of $5,390,000.
Outlook
Repro-Med Systems hasn't issued any earnings guidance for the time being.
Repro-Med Systems hasn't issued any revenue guidance for the time being.
How To Listen To The Conference Call
Date: Aug 11, 2021
Time: 04:30 PM
ET Webcast URL: https://viavid.webcasts.com/starthere.jsp?ei=1479119&tp_key=88143bc632
Technicals
52-week high: $10.34
Company's 52-week low was at $2.70
Price action over last quarter: down 13.67%
Company Profile
Repro-Med Systems Inc develops, manufactures and commercializes easy-to-use specialty infusion solutions that improve quality of life for patients around the world. The FREEDOM Syringe Infusion System currently includes the FREEDOM60 and FreedomEdge Syringe Infusion Drivers, Precision Flow Rate Tubing, and HIgH-Flo Subcutaneous Safety Needle Sets. These devices are used for infusions administered in the home and alternate care settings.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
